Upgrade to SI Premium - Free Trial

Final Patent Interference Decision Favors Sarepta Therapeutics (SRPT) - Baird

September 21, 2016 6:46 AM
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutic (NASDAQ: SRPT) after PTAB issued a decision ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles